Study #2023-0115
A phase 1, multicenter, open-label study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in patients with relapsed/refractory multiple Myeloma (CaMMouflage Trial)
MD Anderson Study Status
Enrolling
Treatment Agent
CB-011
Description
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Multiple Myeloma
Study phase:
Phase I
Physician name:
Neeraj Saini
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.